Back to search results

Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Abroad (travel likely)Recruiting

Conditions

Neuroendocrine Tumors · Gastroenteropancreatic Neuroendocrine Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Clinical Research Institute at Methodist Health System, Dallas, Texas, United States

    Contact: Study coordinator (Colette N Ndjom, MS) · ColetteNgoNdjom@mhd.com · 410-947-4681
    Contact: Study coordinator (Loretta W Bedell, MPH) · lorettabedell@mhd.com · 214-947-4680
    Contact: Principal Investigator (Alejandro Mejia, MD)

  • Methodist Dallas Medical Center, Dallas, Texas, United States

Study leads

  • Alejandro Mejia, MD

    Principal Investigator

    Liver Institute at Methodist Dallas Medical Center

View source on ClinicalTrials.gov(opens in a new tab)